IRWD Q2 2023 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$107M+10.4% YoY

Gross Profit

$88M81.6% margin

Operating Income

-$1.1B-1008.7% margin

Net Income

-$1.1B-989.2% margin

EPS (Diluted)

$-6.84

QoQ Revenue Growth

+3.2%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$35M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$603M

Total Liabilities

$950M

Stockholders' Equity

-$346M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$97M	+10.4%
Gross Profit	$88M	$97M	-9.6%
Operating Income	-$1.1B	$56M	-2046.2%
Net Income	-$1.1B	$37M	-2964.6%

Revenue Segments

Collaborative arrangements revenue

$107M100%

Collaborative arrangement, collaboration and license agreements

$121,0000%

Geographic Segments

North America

$731,00051%

Canada and Mexico

$700,00049%